目的 探讨孟鲁斯特联合布地奈德治疗咳嗽变异性哮喘（CVA）患儿的临床疗效及对肺功能的影响。方法 选取2014年3月-2017年3月渭南市第一医院收治的CVA患儿280例，按照治疗方式分为对照组和观察组，各140例。对照组在常规治疗的基础上给予患儿布地奈德治疗，观察组在对照组的基础上给予孟鲁斯特治疗，两组均治疗60 d。比较两组的临床疗效，治疗前后肺功能指标呼气流量峰值（PEF）、1s用力呼吸容积（FEV1）及一秒率（FEV1/FVC），比较两组不良反应的发生情况。结果 治疗后，观察组临床疗效的总有效率是94.29%，显著高于对照组的77.14%，差异有统计学意义（P<0.05）。两组患儿治疗前的肺功能指标比较无明显差异，两组治疗后以上检测指标较治疗前均显著提高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，观察组PEF、FEV1、FEV1/FVC水平均显著高于对照组，差异有统计学意义（P<0.05）。两组患儿在治疗期间均无严重不良反应的发生，不良反应发生情况无显著差异。结论 孟鲁斯特联合布地奈德治疗咳嗽变异性哮喘比单用布地奈德治疗的临床效果好，可有效改善患儿的肺功能，值得临床推广。

Objective To explore the clinical efficacy of budesonide combined with montelukast in the treatment of children with cough variant asthma and its effect on lung function. Methods Selected 280 cases of children with cough variant asthmain our hospital from March 2014 to March 2017. All patients were divided into control group and observation group by treatment, 140 cases in each group. The control group was treated with budesonide on the basis of conventional treatment, the observation group was treated with montelukast on the basis of control group. The total effective rate was compared between the two groups. The levels of peak expiratory flow (PEF), orced expiratory volume in 1 second (FEV1), forced expired volume inone second to forced vital capacityratio (FEV1/FVC) were compared between the two groups before and after treatment. Results The total effective rate of the observation group was significantly higher than that of the control group (P<0.05) after treatment. There were no significant differences in lung function between the two groups before treatment. The levels of PEF, FEV1, FEV1/FVC in the two groups were significantly higher than those before treatment (P<0.05). The levels of PEF, FEV1 and FEV1/FVC in the observation group were significantly higher than those in the control group (P<0.05) after treatment. There was no significant adverse reaction between the two groups during the treatment, and there was no significant difference in the incidence of adverse reactions. Conclusions Budesonide combined with montelukast treatment of cough variant asthma than budesonide treatment of clinical effect is good, can effectively improve the lung function of children, worthy of clinical promotion.